Journal
VACCINE
Volume 23, Issue 6, Pages 780-788Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2004.07.036
Keywords
tuberculosis; BCG; vaccine
Categories
Funding
- NIAID NIH HHS [N01 AI-75320] Funding Source: Medline
Ask authors/readers for more resources
In this study, we evaluated the protective efficacy of a DNA vaccine (pE6/85) expressing an ESAT6-Ag85B fusion protein against a primary Mycobacterium tuberculosis infection in mice. In short-term studies, vaccination with pE6/85 protected as well as Mycobacterium bovis BCG immunization with similar lung pathology and bacterial burdens detected 28 days after a low dose aerogenic challenge (>1.0 log(10) reduction relative to naives). In a survival experiment, the protection induced by pE6/85 immunization was also not significantly different than that elicited by BCG vaccination with the mean-times-to-death (+/- standard error of the mean) being 102 +/- 20, 271 +/- 32 and 299 +/- 14 days for naive, pE6/85 and BCG-vaccinated mice, respectively. Furthermore, boosting with pE6/85 but not BCG or a DNA vaccine cocktail at 1 year after an initial BCG immunization (when BCG-induced protection was declining), augmented protection in the lung at 15 and 18 months to levels detected at 3 months post-BCG vaccination. (C) 2004 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available